Akademik Veri Yönetim Sistemi
Journal of Drug Delivery Science and Technology, cilt.121, 2026 (SCI-Expanded, Scopus)
The clinical application of highly lipophilic bioactives such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) is limited by poor aqueous solubility, low bioavailability, and inefficient cellular delivery. In this study, we developed lipid-based nanoemulsion carriers for CBD and THC using high-pressure homogenization and microfluidization to address these delivery challenges. The resulting nanoemulsions exhibited ultrafine droplet size, narrow polydispersity, strong electrostatic stability, and encapsulation efficiencies exceeding 99%. The drug delivery performance of the nanoemulsion system was functionally validated in lung cancer cell models, where nanoemulsified cannabinoids demonstrated enhanced cellular uptake, selective cytotoxicity, and pronounced chemosensitizing effects when combined with standard chemotherapeutic agents. Drug–drug interactions were quantified using the Chou–Talalay method, revealing strong synergistic effects and substantial dose-reduction potential. Importantly, nanoemulsion-mediated delivery enabled substantial dose reduction of co-administered chemotherapeutics without compromising efficacy. Mechanistic studies showed that nanoemulsion-mediated delivery of CBD and THC promoted mitochondrial dysfunction and apoptosis-associated signaling, as confirmed by multiple complementary assays. These findings demonstrate that nanoemulsion-based cannabinoid delivery systems can significantly enhance combination therapy outcomes and represent a promising strategy for improving the performance of hydrophobic therapeutics in cancer treatment.